Navigation Links
RNAi Gene Silencing System

Gene silencing by RNA interference (RNAi) in eukaryotic cell cultures requires double-stranded molecules known as short interfering RNA (siRNA). QIAGEN is a licensed supplier of siRNA, offering a custom siRNA oligonucleotide synthesis service, library siRNA directed against common target genes, and a Cancer siRNA Oligo Set for screening a large number of cancer-related genes using RNAi techniques. Features and benefits
  • siRNA synthesis using patented TOM-Amidite chemistry for high-coupling efficiency
  • High-purity siRNA for efficient gene silencing
  • Expert advice on siRNA design for maximizing gene-silencing potential
  • Labeled siRNA allowing transfection to be easily followed
  • siRNA is annealed and ready-to-use in cell transfection
Principle The application of RNAi to mammalian cells has revolutionized the field of functional genomics by allowing targeted inhibition of gene expression using double-stranded RNA (dsRNA) that carries the same sequence as mRNA transcribed from the target gene. In mammalian cell systems, double-stranded siRNA oligos can be used to induce gene silencing.

After siRNAs are delivered to the cytoplasm of a cell, they bind to a multi-protein complex to form an RNA-induced silencing complex (RISC). The siRNA-protein complex targets en
'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Quantification of siRNA Silencing Efficiency Using the LightCycler System
2. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
3. Drive Long-Term Silencing with CMV Vectors
4. Enhanced siRNA Delivery and Long-term Gene Silencing
5. Fast, Accurate Assessment of siRNA-induced Gene Silencing
6. Superior Gene Silencing Using Adenoviral Vectors
7. Your Data: Silencing Hepatitis C Virus Replication With In Vitro Transcribed siRNAs
8. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
9. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
10. Your Data: Silencing Neural Cell Adhesion Genes with In Vitro Transcribed siRNAs
11. Your Data: Silencing of a Pro-apoptotic Transcription Factor Using Synthetic siRNA
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: RNAi Gene Silencing System

(Date:2/27/2015)... ADELAIDE, Australia , Feb. 27, 2015 ... data from the DisrupTOR-1 trial of BNC105 in patients ... Symposium in Orlando, Florida . The ... of the City of Hope Comprehensive Cancer Center ... presentation. The new data identifies Ferritin ...
(Date:2/27/2015)...   PureTech , a science and technology R&D ... and technologies in the healthcare sector, announced today the ... Member of the Board of Directors of Sanofi, to ... been a pleasure to know Chris for many years ... working together more closely now," said Dr. Robert ...
(Date:2/26/2015)... 26, 2015   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today reported ... goals, other key objectives, and financial guidance.  Synageva,s ... at 4:30 p.m. EST to review the financial ... participate in today,s call by telephone, please dial ...
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... SAN DIEGO, June 1, 2011 Tioga Pharmaceuticals, Inc. ... granted Fast Track designation by the U.S. Food and ... diarrhea-predominant irritable bowel syndrome (D-IBS). Tioga is conducting a ... conducted under a Special Protocol Assessment agreement with the ...
... 2011 Reportlinker.com announces that a new ... catalogue: Osteosarcoma Therapeutics - ... http://www.reportlinker.com/p0546797/Osteosarcoma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Market Forecasts to 2017 ...
... a new quasiparticle called the "hybrid plasmon polariton" ... circuits and optical computing for the 21st century. ... Lawrence Berkeley National Laboratory (Berkeley Lab) have demonstrated ... on-chip optical communication systems. "We have ...
Cached Biology Technology:FDA Grants Fast Track Designation to Tioga Pharmaceuticals' Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10Nanoscale waveguide for future photonics 2Nanoscale waveguide for future photonics 3Nanoscale waveguide for future photonics 4
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... mellifera) to the Americas, Mayan bee keepers harvested honey from ... Now, colleagues from the Colegio de la Frontera Sur in ... warn of the imminent demise of stingless bee keeping on ... loss. , "In our initial surveys of bee keepers working ...
... for drug resistance in HIV-infected patients at the time ... life expectancy, according to an article in the Nov. ... , Resistance to antiretroviral therapy, even in patients ... However, genotype resistance testing, which involves looking for the ...
... Covering ship hulls with artificial shark skin could help ... as barnacles on ship hulls is a major cause ... skin offers a structural design that prevents this so ... Applied Sciences, Bremen, Germany, is presenting his work on ...
Cached Biology News:Mayan stingless bee keeping: Going, going, gone? 2Drug resistance testing in treatment-naive HIV patients is cost-effective 2
... The loxP-amp-loxP cassette is designed ... The prokaryotic promoter gb2 driving the ... modified version of the Em7 promoter. It ... used Tn5 promoter. A synthetic polyadenylation signal ...
... be difficult to achieve in many bacterial ... or more restriction and modification (R-M) systems ... as "foreign". TypeOne™ Restriction Inhibitor provides a ... bacterial strains with type I R-M systems. ...
... most widely used in combination with ... stain nucleic acids following polyacrylamide gel ... Pyronin Y stains RNA red, while ... Chem comp: Dye content ≥ ...
... AMPure is a magnetic bead-based ... no sample transfer, centrifugation or ... small and large PCR extension ... microplates. Agencourt AMPure can easily ...
Biology Products: